Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 ...

An experimental obesity drug ... of medication adherence, weight loss results were 13.7% with CagriSema and 3.4% with the placebo. Although the trial results failed to meet Novo Nordisk's ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss ... drug compared to the company's other drugs, Ozempic, which is approved ...

Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $ ... that doesn’t cover obesity medications. Patients could previously buy the drug without insurance for $650 per month ...

Novo Nordisk still has two more Phase 3 trials scheduled for CagriSema, and said Monday it still expects to submit the drug for regulatory approval ... its current weight loss drugs, and are ...